Wednesday, September 9, 2015

News: Regenexx® Announces Positive Results From Largest Knee Osteoarthritis Stem Cell Treatment Study to Date

DENVERSept. 9, 2015 /PRNewswire/ -- Regenexx®, a nationwide network of doctors specializing in regenerative medicine and advanced interventional orthopedic techniques, today announced the results of a peer-reviewed research study of 840 patients treated for knee osteoarthritis. All patients were treated using precise imaging guidance and the patented Regenexx protocol, which obtains stem cells from the patient's own bone marrow.

"We're proud to say that this study represents the largest published human experience with stem cell injections to treat knee arthritis to date," stated Christopher Centeno, M.D., the company's CEO. "No group has published more data on same day stem cell procedures to treat common orthopedic conditions without surgery," added Centeno.
The research study on knee arthritis examined the efficacy and safety of bone marrow and bone marrow plus fat stem cell injections. Most of the study patients were knee replacement candidates. Many patients in the study were able to avoid knee replacement. Self-rated functional and pain scores all showed statistically significant positive changes from baseline in both treatment groups. The study concluded that there was no advantage of adding fat to the joint over just bone marrow stem cells. Safety in both groups was excellent compared to knee replacement.
It's important to note that these studies represent data collected in the Regenexx registry as patients are treated and that this data wasn't collected as part of a randomized controlled trial (RCT) of the type commonly used in drug studies. The company has 3 such RCTs that it has funded. One knee osteoarthritis study being conducted inChicago has completed enrollment, while the other studies for shoulder rotator cuff tears and ACL tears are open and still recruiting in Colorado.
About Regenexx
The Regenexx® Procedures are the nation's most advanced non-surgical stem cell and blood platelet treatments for common joint injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient's own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone.
For more information on Regenexx, please visit:
U.S. National Library of Medicine study abstract:
Media Contact:Mark Testa
(303) 885-9630
SOURCE Regenexx

Related Links

Published at PR Newswire

No comments:

Post a Comment